ALXO catalyst calendar

ALX ONCOLOGY HOLDINGS INC

Upcoming catalysts
3
Cash runway
22.2 months
Cash & investments
$138M
Phase 3 programs
1

ALX ONCOLOGY HOLDINGS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 22.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 4, 2026 est. Next quarterly earnings (projected) Earnings —
June 15, 2027 A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors Trial Milestone Phase 1
December 15, 2027 ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Trial Milestone Phase 2

Track ALXO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ALXO in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
June 30, 2026 8-K filed: Leadership change, Reg FD disclosure, Other event Corporate —
June 26, 2026 8-K filed: Material agreement Corporate —
May 8, 2026 Quarterly results filed (8-K) Earnings —
April 13, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
February 27, 2026 Quarterly results filed (8-K) Earnings —
January 30, 2026 8-K filed: Other event Filing —
January 30, 2026 8-K filed: Material agreement, Other event Corporate —
January 21, 2026 8-K filed: Leadership change Corporate —
November 7, 2025 Quarterly results filed (8-K) Earnings —
September 12, 2025 8-K filed: Leadership change, Other event Corporate —
August 12, 2025 Quarterly results filed (8-K) Earnings —
June 27, 2025 A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) Trial Milestone Phase 1
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 25, 2025 8-K filed: Listing / standard notice Corporate —
March 3, 2025 Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) Trial Milestone Phase 2
March 3, 2025 Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Trial Milestone Phase 2
January 17, 2025 A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) Trial Milestone Phase 1
May 24, 2024 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Trial Milestone Phase 2/Phase 3
May 5, 2023 A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) Trial Milestone Phase 1
February 1, 2022 A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.